Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban

Journal of Thrombosis and Thrombolysis

Volumn 19, Issue 1, 2005, Pages 65-69

  Job, Harenberg ^a   Ingrid, Jörg ^a   Tivadar, Fenyvesi ^a   Lukas, Piazolo ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anticoagulation; Argatroban; Heparin induced thrombocytopenia; Lepirudin

Indexed keywords

ARGATROBAN; CROSS REACTING ANTIBODY; DRUG ANTIBODY; ECARIN; HEPARIN; HIRUDIN; IMMUNOGLOBULIN G; LEPIRUDIN; PHENPROCOUMON; THROMBIN INHIBITOR;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TIME; CASE REPORT; DRUG ERUPTION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAS CHROMATOGRAPHY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOGLOBULIN PRODUCTION; MALE; MASS SPECTROMETRY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOEMBOLISM;

AGED; ANTIBODIES; ANTICOAGULANTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN; HIRUDIN THERAPY; HIRUDINS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PIPECOLIC ACIDS; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 21844459237     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-005-0942-4     Document Type: Article

References (19)

1. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: A critical review. Arch Intern Med 2004;164:361-364. 10.1001/archinte.164.4.361
2. Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: Association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation. Lancet 1982;2:1246-1249. 10.1016/S0140-6736(82)90106-4
3. Greinacher A, Völpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. The HIT Investigators Group. Circulation 1999;99:73-80. 1:CAS:528:DyaK1MXnsFCktw%3D%3D
4. Harenberg J, Huhle G, Piazolo L, Wang LU, Heene DL. Anticoagulation in patients with heparin-induced thrombocytopenia type II. Semin Thromb Hemost 1997;23:189-196. 1:STN:280:ByiA2czot1w%3D
5. Harenberg J, Hoffmann U, Huhle G, Song XH, Wang LC. Treatment of an acute flush reaction caused by subcutaneous r-hirudin with pegylated hirudin. Br J Haematol 2000;108 528-530. 10.1046/j.1365-2141.2000.01837.x
6. Lewis BE, Wallis DE, Berkowitz SD, et al. for the ARG 911 Study Investigators: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103;1838-1843. 1:CAS:528:DC%2BD3MXjsFGhsLs%3D
7. Walenga JM, Ahmad S, Hoppensteadt D, Iqbal O, Hursting MJ, Lewis BE. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 2002;105:401-405. 10.1016/ S0049-3848(02)00049-X
8. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991;66:734-736. 1:STN:280:By2C2sbpvFY%3D
9. Song X, Huhle G, Wang L, Hoffmann U, Harenberg J. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 1999;100:1528-1532. 1:CAS:528:DyaK1MXmvVWhtLs%3D
10. Huhle G, Hoffmann U, Song X, Wang LC, Heene DL, Harenberg J. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol 1999;106; 195-201. 10.1046/ j.1365-2141.1999.01532.x
11. Greinacher A, Eichler P, Albrecht D, Strobel U, Pötzsch B, Eriksson B. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: Incidence and clinical relevance. Blood 2003;101:2617-2619. 10.1182/blood-2002-04-1055
12. Harenberg J, Huhle G, Wang C, Hoffmann U, Song XH. Re-exposure to recombinant r-hirudin in antihirudin antibody-positive patients with a history of heparin-induced thrombocytopenia. Br J Haematol 2000;109:360-363. 10.1046/j.1365-2141.2000.02005.x
13. Bircher AJ, Czendlik SH, Langauer Messmer S, Müller Ph, Howald h. Acute urticaria caused by sub cutaneous recombinant hirudin: Evidence for an IgG-mediated hypersensitivity reaction. J Allergy Clin Immunol 1996;98:994-996. 1:STN:280:ByiD1Mzmt1w%3D
14. EMEA public health statement on refludan (lepirudin) - fatal anaphylactic reactions-. Document reference: EMEA/H/27717/02/2/en. http://www.emea.eu.int.
15. Greinacher S, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003;108:2062-2065. 10.1161/ 01.CIR.0000096056.37269.14
16. Close P, Bichler J, Kerry R, et al. Weak allergenicity of recombinant hirudin CGP39393 (REVASC) in immunocompetent volunteers: The European Hirudin in Thrombosis Group (HIT Group). Coron Art Dis 1994;5:943-949. 1:STN:280:ByqB3srotlA%3D
17. Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low molecular weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-1335. 10.1056/NEJM199711063371901
18. Wieder KJ, Palczuk NC, van Es T, David FF. Some properties of polyethylene glycan phenylalanine ammonia-lyase adducts. J Biol Chem 1979;254:12579-12583. 1:CAS:528:DyaL3cXisVeq
19. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-329. 10.1592/phco.20.4.318.34881